Shots:

• The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26- 2021 cutoff data
• The preliminary efficacy analysis in both population showed cORR (41% & 48%); 3 patients achieved SD with tumor regression of -21%- -23% & -27% in TKI-naïve; DoR (1.9+ to 7.4+ & 0.9+ to 15.1mos.)- duration of treatment (0.9 to 30.7+ & 0.6 to 20.8mos.)
• In 23 pretreated patients- 13 (57%) had NTRK solvent front mutations; cORR (62%)- DoR (0.9+ to 13.7mos.)- 3 patients had uPRs- 2 uPRs have been confirmed & 3rd patients were on treatment awaiting- was well tolerated- treatment discontinuation due to TEAEs (11%)

  | Ref: Globe Newswire | Image: Businesswire